Singapore markets open in 6 minutes

LLY Dec 2022 490.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.60000.0000 (0.00%)
As of 09:56AM EDT. Market open.
Full screen
Previous close0.6000
Open0.3400
Bid0.0100
Ask0.9900
Strike490.00
Expiry date2022-12-16
Day's range0.3400 - 0.6000
Contract rangeN/A
Volume4
Open interest190
  • Zacks

    LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

    The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.

  • Motley Fool

    Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today

    Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease. The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.

  • Zacks

    Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study

    Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.